Public Health Emergency - Leading a Nation Prepared
To help prevent hospitalizations, HHS and the Department of Defense are purchasing additional doses of a COVID-19 therapeutic, bamlanivimab. ASPR is using a data-driven approach to ensure fair and equitable distribution of the product to our state and territorial partners
ASPR is pleased to announce that Dr. Gary Disbrow has been selected as the new Director of the Biomedical Advanced Research and Development Authority (BARDA) after serving as the acting BARDA director since April 2020. Under Dr. Disbrow’s leadership, BARDA has built a portfolio of more than 70 medical countermeasures to fight the COVID-19 pandemic.
Antibiotic resistance continues to harm American lives every year. Tools for surveillance, early detection, containment, treatment, and prevention are key to addressing the spread of infections and treating disease. BARDA remains as committed as ever to fostering public-private partnerships to revitalize the antibacterial pipeline and combat antibiotic resistance.
ASPR’s Strategic National Stockpile is partnering with McKesson to provide supply kits with needles, syringes, PPE and alcohol pads to ensure healthcare workers have the supplies needed to safely administer COVID-19 vaccines when available.
BARDA is collaborating with the Department of Defense at Warp Speed to purchase a monoclonal antibody treatment for COVID-19 from Eli Lilly if the drug achieves FDA authorization. These doses would be allocated to states for use in outpatient care.
